Gliomas are rare and fatal brain tumors that form when glial cells in the body grow uncontrollably. Glial cells usually support nerves in the body by helping an individual’s central nervous system function. These deadly tumors typically grow in the brain but may, in some cases, also grow in the spinal cord.
New research has discovered that gliomas adapt to their surrounding brain environment in response to cancer treatment, developing interactions with nearby immune cells and neurons that prevent tumor cells from being identified easily by the body’s immune system. The study was conducted by an international team of experts, which included researchers from the University of Leeds.
The overall main objective of the study is to find a cure for this deadly brain cancer. At the moment, gliomas have no cure, which makes their diagnosis all the more devastating. While low-grade forms of this cancer have a better rate of survival, they often transition to high-grade gliomas. Figures show that more than 90% of patients with these tumors die some five years following their diagnosis.
For this study, scientists focused on finding out why gliomas transitioned to higher-grade forms as well as how they adapted and continued to grow once treatment began. The investigators gathered multiple glioma samples as they advanced to high-grade tumors, prior to and after treatment. They observed how the tumor cells changed and adapted in an effort to find new ways to prevent this from happening using new drugs. The scientists discovered that low-grade tumors often developed new mutations that allowed their cells to begin dividing more rapidly, which hastened their development into high-grade tumors.
Current treatments for gliomas include radiation therapy, surgery and chemotherapy. However, this may not be enough, as the study’s findings highlight the need to supplement these therapies with new treatments.
The lead UK academic for this research, associate professor Lucy Stead of the University of Leeds, stated that the brain was a complex organ made up of different cells types and brain tumors were equally complicated and diverse. Stead, who specializes in brain cancer biology, explained that the best way to cure the illness was to learn from patient tissue, noting that this research had afforded them insight into how gliomas progressed.
The study’s findings, which were published in “Cell,” will help experts find ways to target previously unknown cellular interactions and hopefully in the future, cure the fatal illness.
As more becomes known about the different mechanisms behind the proliferation of malignant tumors, entities such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) stand a high chance of formulating new therapeutics that will deliver better clinical outcomes in the treatment of brain and central nervous system cancers.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
